Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Ren, Wuze ^a   Mumbauer, Alexandra ^a   Zhuang, Ke ^a   Harbison, Carole ^b   Knight, Heather ^b   Westmoreland, Susan ^b   Gettie, Agegnehu ^a   Blanchard, James ^c   Cheng Mayer, Cecilia ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Antiviral antibody response; Coreceptor switch; Macrophage infection; R5 SHIV molecular clone

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORECEPTOR SWITCHING; DISEASE COURSE; ENVELOPE GENE; HOST SELECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; LYMPH NODE; MACROPHAGE; MOLECULAR CLONING; MOLECULAR GENETICS; NONHUMAN; PHENOTYPE; RETROVIRUS INFECTION; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TUMOR ESCAPE; VIRUS ISOLATION; VIRUS TRANSMISSION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; MACACA MULATTA; MUCOUS MEMBRANE; RECEPTORS, CCR5; RECEPTORS, HIV; RECOMBINATION, GENETIC; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL TROPISM; VIRUS INTERNALIZATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84873047039     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-9     Document Type: Article

References (96)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700. 10.1146/annurev.immunol.17.1.657, 10358771.
2. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360. 240857, 1738194.
3. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994, 94:2060-2067. 10.1172/JCI117560, 294642, 7962552.
4. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181. 10.1126/science.8356453, 8356453.
5. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 2002, 18:567-576. 10.1089/088922202753747914, 12036486.
6. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105:7552-7557. 10.1073/pnas.0802203105, 2387184, 18490657.
7. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265. 10.1038/nm1197-1259, 9359702.
8. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997, 185:621-628. 10.1084/jem.185.4.621, 2196142, 9034141.
9. Esbjornsson J, Mansson F, Martinez-Arias W, Vincic E, Biague AJ, da Silva ZJ, Fenyo EM, Norrgren H, Medstrand P. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 2010, 7:23. 10.1186/1742-4690-7-23, 2855529, 20307309.
10. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, Papathanasopoulos MA. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 2008, 22:896-899. 10.1097/QAD.0b013e3282f57f7a, 18427209.
11. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
12. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974. 10.1093/infdis/169.5.968, 7909549.
13. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005, 13:269-277. 10.1016/j.tim.2005.04.005, 15936659.
14. Pastore C, Ramos A, Mosier DE. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004, 78:7565-7574. 10.1128/JVI.78.14.7565-7574.2004, 434079, 15220431.
15. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, Carnegie G, Desselberger U, Gray PW, Weiss RA, Clapham PR. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996, 70:8355-8360. 190923, 8970955.
16. Cornelissen M, Mulder-Kampinga G, Veenstra J, Zorgdrager F, Kuiken C, Hartman S, Dekker J, van der Hoek L, Sol C, Coutinho R, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol 1995, 69:1810-1818. 188790, 7853521.
17. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis 1997, 175:231-232. 10.1093/infdis/175.1.231, 8985228.
18. Tersmette M, Miedema F. Interactions between HIV and the host immune system in the pathogenesis of AIDS. AIDS 1990, 4(Suppl 1):S57-66.
19. Pratt RD, Shapiro JF, McKinney N, Kwok S, Spector SA. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis 1995, 172:851-854. 10.1093/infdis/172.3.851, 7658081.
20. Abbate I, Vlassi C, Rozera G, Bruselles A, Bartolini B, Giombini E, Corpolongo A, D'Offizi G, Narciso P, Desideri A, et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 2011, 25:611-617. 10.1097/QAD.0b013e328343489e, 21160417.
21. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993, 7:1035-1040. 10.1097/00002030-199308000-00002, 8104421.
22. Fiore JR, Bjorndal A, Peipke KA, Di Stefano M, Angarano G, Pastore G, Gaines H, Fenyo EM, Albert J. The biological phenotype of HIV-1 is usually retained during and after sexual transmission. Virology 1994, 204:297-303. 10.1006/viro.1994.1534, 8091660.
23. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994, 32:364-370. 263037, 7908672.
24. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, Vogelaers D, Vandekerckhove L, Plum J, Verhofstede C. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 2012, 205:174-184. 10.1093/infdis/jir714, 22147802.
25. Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol 2007, 81:525-531. 10.1128/JVI.01983-06, 1797458, 17079299.
26. Vodros D, Thorstensson R, Biberfeld G, Schols D, De Clercq E, Fenyo EM. Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally Infected with simian immunodeficiency virus (SIVsm). Virology 2001, 291:12-21. 10.1006/viro.2001.1164, 11878872.
27. Felber BK, Valentin A, von Gegerfelt A, Jalah R, Patel V, Kulkarni V, Alicea C, Rosati M, Khan A, Draghia-Akli R, Pavlakis GN. P18-09. Persistent virological benefit in SIV-infected macaques upon therapeutic vaccination upon vaccination with DNA vectors. Retrovirology 2009, 6(Suppl 3).
28. Varela M, Landskron L, Lai RP, McKinley TJ, Bogers WM, Verschoor EJ, Dubbes R, Barnett SW, Frost SD, Heeney JL. Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection. J Virol 85:10332-10345.
29. Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008, 5:e173. 10.1371/journal.pmed.0050173, 2504486, 18700814.
30. Veazey RS, Shattock RJ, Klasse PJ, Moore JP. Animal models for microbicide studies. Curr HIV Res 2012, 10:79-87. 10.2174/157016212799304715, 22264049.
31. Van Rompay KK. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses 2012, 28:16-35. 10.1089/aid.2011.0234, 21902451.
32. Joag SV, Li Z, Foresman L, Stephens EB, Zhao LJ, Adany I, Pinson DM, McClure HM, Narayan O. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 1996, 70:3189-3197. 190182, 8627799.
33. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928. 190741, 8794335.
34. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA 1995, 92:7490-7494. 10.1073/pnas.92.16.7490, 41365, 7638218.
35. Igarashi T, Endo Y, Englund G, Sadjadpour R, Matano T, Buckler C, Buckler-White A, Plishka R, Theodore T, Shibata R, Martin M. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc Natl Acad Sci USA 1999, 96:14049-14054. 10.1073/pnas.96.24.14049, 24188, 10570196.
36. Chen Z, Zhao X, Huang Y, Gettie A, Ba L, Blanchard J, Ho DD. CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic Simian/Human Immunodeficiency Virus (SHIV). J Acquir Immune Defic Syndr 2002, 30:133-145.
37. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999, 284:816-819. 10.1126/science.284.5415.816, 10221916.
38. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, Chenine AL, Kramer VG, Siddappa NB, Xu W, Else JG, et al. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 2008, 5:94. 10.1186/1742-4690-5-94, 2576354, 18928523.
39. Pal R, Taylor B, Foulke JS, Woodward R, Merges M, Praschunus R, Gibson A, Reitz M. Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J Acquir Immune Defic Syndr 2003, 33:300-307. 10.1097/00126334-200307010-00003, 12843740.
40. Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J Virol 2012, 86:8516-8526. 10.1128/JVI.00644-12, 3421705, 22647691.
41. Ho SH, Tasca S, Shek L, Li A, Gettie A, Blanchard J, Boden D, Cheng-Mayer C. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J Virol 2007, 81:8621-8633. 10.1128/JVI.00759-07, 1951359, 17537860.
42. Ren W, Tasca S, Zhuang K, Gettie A, Blanchard J, Cheng-Mayer C. Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection. J Virol 84:340-351.
43. Tasca S, Ho SH, Cheng-Mayer C. R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. J Virol 2008, 82:7089-7099. 10.1128/JVI.00570-08, 2446975, 18480460.
44. Shakirzyanova M, Ren W, Zhuang K, Tasca S, Cheng-Mayer C. Fitness disadvantage of transitional intermediates contributes to dynamic change in the infecting-virus population during coreceptor switch in R5 simian/human immunodeficiency virus-infected macaques. J Virol 2010, 84:12862-12871. 10.1128/JVI.01478-10, 3004298, 20943985.
45. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005, 21:171-189. 10.1089/aid.2005.21.171, 15725757.
46. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:6777-6780. 240176, 1404617.
47. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187. 241084, 1560543.
48. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003, 77:13376-13388. 10.1128/JVI.77.24.13376-13388.2003, 296044, 14645592.
49. De Wolf F, Hogervorst E, Goudsmit J, Fenyo EM, Rubsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala SD, et al. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994, 10:1387-1400. 10.1089/aid.1994.10.1387, 7888192.
50. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007, 23:415-426. 10.1089/aid.2006.0130, 17411375.
51. Nishimura Y, Shingai M, Willey R, Sadjadpour R, Lee WR, Brown CR, Brenchley JM, Buckler-White A, Petros R, Eckhaus M, et al. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 2010, 84:4769-4781. 10.1128/JVI.02279-09, 2863788, 20147396.
52. Ince WL, Zhang L, Jiang Q, Arrildt K, Su L, Swanstrom R. Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol 2010, 84:2740-2752. 10.1128/JVI.02180-09, 2826074, 20042504.
53. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149. 10.1073/pnas.0630530100, 153062, 12644702.
54. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007, 196:304-312. 10.1086/518797, 17570119.
55. Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005, 19:1443-1448. 10.1097/01.aids.0000183633.06580.8a, 16135896.
56. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006, 80:4909-4920. 10.1128/JVI.80.10.4909-4920.2006, 1472081, 16641282.
57. Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009, 199:1638-1647. 10.1086/598965, 19432546.
58. Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, et al. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2010, 54:470-476. 10.1097/QAI.0b013e3181e2cba0, 2917795, 20672447.
59. Hsu M, Ho SH, Balfe P, Gettie A, Harouse J, Blanchard J, Cheng-Mayer C. A CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. J Acquir Immune Defic Syndr 2005, 40:383-387. 10.1097/01.qai.0000184857.39318.4f, 16280691.
60. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 2006, 80:8729-8738. 10.1128/JVI.00558-06, 1563858, 16912320.
61. Ho O, Larsen K, Polacino P, Li Y, Anderson D, Song R, Ruprecht RM, Hu SL. Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology 2009, 6:65. 10.1186/1742-4690-6-65, 2720380, 19602283.
62. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, Plum J, Vogelaers D, Stuyver L. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009, 50:126-136. 10.1097/QAI.0b013e31819118fa, 19131897.
63. Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, Boeser-Nunnink B, Stewart-Jones GB, Kootstra NA, van 't Wout AB, Schuitemaker H. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 2010, 405:492-504. 10.1016/j.virol.2010.06.029, 20638697.
64. Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, Petropoulos CJ, Coakley E, Schuitemaker H, Harrigan PR, van 't Wout AB. Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog 2011, 7:e1002106. 10.1371/journal.ppat.1002106, 3121885, 21731496.
65. Navis M, Matas DE, Rachinger A, Koning FA, van Swieten P, Kootstra NA, Schuitemaker H. Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs. PLoS One 2008, 3:e2422. 10.1371/journal.pone.0002422, 2409968, 18560583.
66. Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993, 260:1513-1516. 10.1126/science.8502996, 8502996.
67. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994, 68:2253-2259. 236701, 8139010.
68. Koito A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995, 206:878-884. 10.1006/viro.1995.1010, 7856100.
69. Carrillo A, Ratner L. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 1996, 70:1310-1316. 189949, 8551601.
70. Hoffman TL, Stephens EB, Narayan O, Doms RW. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc Natl Acad Sci USA 1998, 95:11360-11365. 10.1073/pnas.95.19.11360, 21647, 9736741.
71. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, Cho MW. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J Virol 2001, 75:5998-6006. 10.1128/JVI.75.13.5998-6006.2001, 114315, 11390601.
72. Sullivan N, Thali M, Furman C, Ho DD, Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993, 67:3674-3679. 237724, 8497077.
73. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995, 69:5723-5733. 189432, 7543586.
74. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405, 9641677.
75. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953. 10.1126/science.280.5371.1949, 9632396.
76. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000, 74:1961-1972. 10.1128/JVI.74.4.1961-1972.2000, 111674, 10644369.
77. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80:750-758. 10.1128/JVI.80.2.750-758.2006, 1346864, 16378977.
78. Shakirzyanova M, Tsai L, Ren W, Gettie A, Blanchard J, Cheng-Mayer C. Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J Virol 2012, 86:9432-9442. 10.1128/JVI.00852-12, 22740397.
79. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Karim SS, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004, 363:619-622. 10.1016/S0140-6736(04)15596-7, 14987889.
80. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Chohan BH, Kreiss JK, Overbaugh J. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003, 77:12921-12926. 10.1128/JVI.77.23.12921-12926.2003, 262567, 14610215.
81. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009, 83:3556-3567. 10.1128/JVI.02132-08, 2663249, 19193811.
82. Malim MH, Emerman M. HIV-1 sequence variation: drift, shift, and attenuation. Cell 2001, 104:469-472. 10.1016/S0092-8674(01)00234-3, 11239404.
83. Montaner LJ, Crowe SM, Aquaro S, Perno CF, Stevenson M, Collman RG. Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol 2006, 80:961-964. 10.1189/jlb.0806488, 17948340.
84. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, Hirsch V, Martin MA. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001, 98:658-663. 10.1073/pnas.98.2.658, 14644, 11136236.
85. Zhuang K, Finzi A, Tasca S, Shakirzyanova M, Knight H, Westmoreland S, Sodroski J, Cheng-Mayer C. Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One 2011, 6:e21350. 10.1371/journal.pone.0021350, 3132741, 21760891.
86. Schutten M, van Baalen CA, Guillon C, Huisman RC, Boers PH, Sintnicolaas K, Gruters RA, Osterhaus AD. Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure. J Virol 2001, 75:2706-2709. 10.1128/JVI.75.6.2706-2709.2001, 115895, 11222694.
87. Vojnov L, Martins MA, Bean AT, Veloso de Santana MG, Sacha JB, Wilson NA, Bonaldo MC, Galler R, Stevenson M, Watkins DI. The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. J Virol 2012, 86:4682-4687. 10.1128/JVI.06324-11, 3318662, 22318140.
88. Koppensteiner H, Banning C, Schneider C, Hohenberg H, Schindler M. Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol 2012, 86:2826-2836. 10.1128/JVI.05915-11, 3302290, 22205742.
89. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
90. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666. 10.1038/381661a0, 8649511.
91. Ho SH, Martin F, Higginbottom A, Partridge LJ, Parthasarathy V, Moseley GW, Lopez P, Cheng-Mayer C, Monk PN. Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1. J Virol 2006, 80:6487-6496. 10.1128/JVI.02539-05, 1488983, 16775336.
92. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008, 8:619-630. 10.1038/nri2357, 2963026, 18617886.
93. Delwart EL, Gordon CJ. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 1997, 12:348-354. 10.1006/meth.1997.0489, 9245616.
94. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948. 10.1093/bioinformatics/btm404, 17846036.
95. Schwartz AJ, Alvarez X, Lackner AA. Distribution and immunophenotype of DC-SIGN-expressing cells in SIV-infected and uninfected macaques. AIDS Res Hum Retroviruses 2002, 18:1021-1029. 10.1089/08892220260235380, 12396454.
96. Yearley JH, Kanagy S, Anderson DC, Dalecki K, Pauley DR, Suwyn C, Donahoe RM, McClure HM, O'Neil SP. Tissue-specific reduction in DC-SIGN expression correlates with progression of pathogenic simian immunodeficiency virus infection. Dev Comp Immunol 2008, 32:1510-1521. 10.1016/j.dci.2008.06.006, 18606180.